+6M	Six or more months after the establishment SGLT2i treatment
3M	Three months after the establishment SGLT2i treatment
CKD	Chronic kidney disease
CVD	Cardiovascular disease
DBP	Diastolic blood pressures
DMSO	Dimethylsulfoxide
ECAR	Extracellular acidification rate
ETC	Electron transport chain
eGFR	Glomerular filtration rate
FCCP	Carbonylcyanide-p-trifluoromethoxyphenylhydrazone
PBMCs	Peripheral blood mononuclear cells
PHA	Phytohemagglutinin
PRE	Before the establishment SGLT2i treatment
OCR	Oxygen consumption rate
OXPHOS	Oxidative phosphorylation
ROS	Reactive oxygen species
SD	Standard deviation
SBP	Systolic blood pressures
SGLT2	Sodium-glucose co-transporter 2
SGLT2i	Sodium-glucose co-transporter 2 inhibitors
T2D	Type 2 diabetes
TMRM	Tetramethylrhodamine